Company News: Gilead Sciences, Cubist Pharmaceuticals and Calixa Therapeutics

Share this article:
Gilead Sciences said that it will likely end development of darusentan, a once promising endothelin receptor antagonist for treating resistant hypertension, because the agent did not achieve its co-primary endpoints in a phase III trial.

Cubist Pharmaceuticals said it plans to acquire privately held Calixa Therapeutics for $92.5 million in cash and up to $310 million in milestone payments. In the deal, expected to close by year's end, Cubist would obtain Calixa's rights to develop and commercialize the firm's Phase 2 antibiotic CXA-201, which is intended to treat common, serious Gram-negative infections.
Share this article:

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.